Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

996
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
996
Drug Nomenclature01:17

Drug Nomenclature

3.3K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
3.3K
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

426
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
426
Nonlinear Pharmacokinetics: Overview01:19

Nonlinear Pharmacokinetics: Overview

1.4K
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
1.4K
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

398
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
398

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multi-scale data improves performance of machine learning model for long COVID identification.

Communications medicine·2026
Same author

Governing real-world health data as a public utility.

Science (New York, N.Y.)·2026
Same author

LinkML: an open data modeling framework.

GigaScience·2025
Same author

Development of a robust corpus for automated evaluation of online health information in Chinese using the DISCERN scale.

Journal of the American Medical Informatics Association : JAMIA·2025
Same author

Advancing the science of genomic learning healthcare systems.

Learning health systems·2025
Same author

Mondo: integrating disease terminology across communities.

Genetics·2025
Same journal

LabSage: Structural-Semantic Decoupling for Enhanced Retrieval-Augmented Generation in Clinical Laboratories.

AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science·2026
Same journal

Evaluating Representation Embeddings from LLMs and Time-Series Foundation Models for Wearable Accelerometer-Based Health Prediction.

AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science·2026
Same journal

ClinNoteAgents: An LLM Multi-Agent System for Predicting and Interpreting Heart Failure 30-Day Readmission from Clinical Notes.

AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science·2026
Same journal

Mapping the Storm: Linking Tornado Paths to Emergency Room Surges Through Geocoded Patient Data.

AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science·2026
Same journal

Multi-Modal Deep Learning-Based Model to Predict Burkitt Lymphoma Recurrence.

AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science·2026
Same journal

A Multi-Model LLM Consensus Framework to Identify EHR-Predictable Eligibility Criteria in NSCLC Immunotherapy Trials.

AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science·2026
See all related articles

Related Experiment Video

Updated: May 5, 2026

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
12:41

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Published on: December 23, 2022

5.9K

PharmGKB Drug Data Normalization with NDF-RT.

Qian Zhu1, Robert R Freimuth, Jyotishman Pathak

  • 1Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.

AMIA Joint Summits on Translational Science Proceedings. AMIA Joint Summits on Translational Science
|December 5, 2013
PubMed
Summary
This summary is machine-generated.

This study harmonizes pharmacogenomics drug data from PharmGKB with the National Drug File Reference Terminology (NDF-RT) for better clinical integration. Mapping these drug terminologies enhances data exchange and interpretation in pharmacogenomics applications.

More Related Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K

Related Experiment Videos

Last Updated: May 5, 2026

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
12:41

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Published on: December 23, 2022

5.9K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K

Area of Science:

  • Pharmacogenomics
  • Biomedical Informatics
  • Clinical Terminology

Background:

  • The Pharmacogenomics Knowledge Base (PharmGKB) is a crucial resource for pharmacogenomics data.
  • Clinical integration of pharmacogenomics necessitates standardized drug terminologies.
  • Harmonizing PharmGKB drug data with clinical terminologies facilitates data exchange and interpretation.

Purpose of the Study:

  • To map drugs and drug classes from PharmGKB to the National Drug File Reference Terminology (NDF-RT).
  • To enhance the integration and usability of pharmacogenomics data in clinical practice.
  • To support data representation, interpretation, and exchange across diverse systems.

Main Methods:

  • Extraction of drug and drug class information from PharmGKB.
  • Mapping extracted entities to the National Drug File Reference Terminology (NDF-RT).
  • Utilizing RxNorm as the integrated terminology standard.

Main Results:

  • Successful mapping of PharmGKB drug data to NDF-RT.
  • Evaluation of mapping results for accuracy and utility.
  • Provision of evaluated mapping for PharmGKB's consideration.

Conclusions:

  • Harmonizing PharmGKB drug data with NDF-RT improves data interoperability.
  • Standardized terminologies are essential for clinical pharmacogenomics applications.
  • This work supports the broader integration of pharmacogenomics knowledge into healthcare.